Understanding how glioblastoma tumors respond to immunotherapy
Identifying the Determinants of Immunoediting During Glioblastoma Immunotherapy
This study is looking at why some people with glioblastoma, a type of brain cancer, respond better to immunotherapy treatments than others, by exploring the tumor's environment and its cells to find out what makes a difference in treatment success.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Harvard Medical School NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11065981 on NIH RePORTER |
What this research studies
This research investigates the factors that influence how glioblastoma, a type of brain cancer, responds to immunotherapy treatments like anti-PD-1 therapy. It focuses on the tumor's microenvironment and cellular characteristics that may affect treatment efficacy. By analyzing different tumor cell states, particularly those that are more resistant to standard therapies, the research aims to identify why some patients benefit from immunotherapy while others do not. The approach includes examining the immune response and tumor characteristics in patients undergoing treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma who are considering or currently undergoing immunotherapy.
Not a fit: Patients with glioblastoma who are not eligible for immunotherapy or those with other types of brain tumors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved immunotherapy strategies for glioblastoma patients, potentially enhancing survival rates.
How similar studies have performed: Previous research has shown promise in understanding immunotherapy responses in other cancers, suggesting that this approach may yield valuable insights for glioblastoma as well.
Where this research is happening
Boston, United States
- Harvard Medical School — Boston, United States (Active)
Researchers
- Principal investigator: Ghannam, Jack — Harvard Medical School
- Study coordinator: Ghannam, Jack
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.